Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML 18 Pilot Trial of AC220, plerixafor, or ganetespib with chemotherapy in older patients with AML or high-risk MDS
2010-021444-18Phase 2Completed
- Sponsor
- Cardiff University
- Start
- Oct 2010
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of quizartinib, plerixafor, ganetespib and clofarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Cardiff University. Primary endpoints: Feasibility of combining investigational agent with chemotherapy and Toxicity. Started Oct 2010; status: completed.
02
Drugs
quizartinibplerixaforganetespibclofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2010-021444-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021444-18.